{"id":3150,"date":"2024-06-10T11:22:29","date_gmt":"2024-06-10T15:22:29","guid":{"rendered":"https:\/\/cytel.agencyukdev.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/"},"modified":"2024-08-21T11:16:16","modified_gmt":"2024-08-21T15:16:16","slug":"cdisc-sdtm-and-adam-an-explosive-2021-ending","status":"publish","type":"perspectives","link":"https:\/\/cytel.agencyukdev.com\/fr\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/","title":{"rendered":"CDISC SDTM and ADaM: An Explosive 2021 Ending!"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-4746\" src=\"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Header-V1.2.webp\" alt=\"\" width=\"860\" height=\"365\" srcset=\"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Header-V1.2.webp 860w, https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Header-V1.2-300x127.webp 300w, https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Header-V1.2-473x201.webp 473w\" sizes=\"auto, (max-width: 860px) 100vw, 860px\" \/><\/p>\n<p>Recently, on November 29 I received an email from CDISC announcing an important update for both SDTM and ADaM CDISC models: in one single day CDISC was able to release for both SDTM <sup>[1,2]<\/sup> and ADaM <sup>[3]<\/sup>, a new Implementation Guidance (IG) along with other related documents, and also a new version of the standard for SDTM. The following table summarizes the release:<\/p>\n<p>&nbsp;<\/p>\n<p><!--more--><\/p>\n<div style=\"overflow-x: auto; max-width: 100%; width: 100%; margin-left: auto; margin-right: auto;\" data-hs-responsive-table=\"true\">\n<table style=\"width: 100%; border-collapse: collapse; table-layout: fixed; border: 1px solid #99acc2; height: 347px;\">\n<tbody>\n<tr style=\"height: 39px;\">\n<td style=\"width: 50%; padding: 4px; text-align: left; height: 39px; background-color: #52c9f4;\"><strong>Standard<\/strong><\/td>\n<td style=\"width: 50%; padding: 4px; height: 39px; background-color: #52c9f4;\"><strong>Updated Content<\/strong><\/td>\n<\/tr>\n<tr style=\"height: 88px;\">\n<td style=\"width: 50%; padding: 4px; height: 88px;\">SDTM<\/td>\n<td style=\"width: 50%; padding: 4px; height: 88px;\">\n<ul>\n<li>SDTM Standard Version 2.0<\/li>\n<li>SDTM Implementation Guidance Version 3.4<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr style=\"height: 219px;\">\n<td style=\"width: 50%; padding: 4px; height: 219px;\">ADaM<\/td>\n<td style=\"width: 50%; padding: 4px; height: 219px;\">\n<ul>\n<li>ADaM Implementation Guidance Version 1.3<\/li>\n<li>ADaM OCCDS Implementation Guidance Version 1.1<\/li>\n<li>ADaM Implementation Guidance for Medical Device Version 1.0<\/li>\n<li>ADaM Implementation Guidance for Non-Compartmental Analysis Version 1.0<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>&nbsp;<\/p>\n<p>Together with the above updates, both SDTM and ADaM teams were able to release the updated conformance Rules. All the new standards and IGs are available in the CDISC Library.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"font-weight: bold;\"><span style=\"color: #2e308d;\">What&#8217;s new in ADaM<\/span><\/p>\n<p>The &#8220;family&#8221; of ADaM documentation has been now enriched with two new elements:<\/p>\n<ol>\n<li><strong><span style=\"color: #52c9f4;\">ADaM IG for Medical Device<\/span><\/strong>: this IG introduces an adapted version of the three standard ADaM classes (ADDL for ADSL, MDBDS for BDS and MDOCCDS for OCCDS) to support the typical statistical analysis needs for clinical trials using medical devices. If you want a nice summary of the IG and real examples, I recommend the paper from PharmaSUG 2021 co-authored by my colleague Silvia Faini<sup>[4]<\/sup>.<\/li>\n<li><strong><span style=\"color: #52c9f4;\">ADaM IG for Non-Compartmental Analysis (NCA)<\/span><\/strong>: this IG does not introduce any new ADaM class but rather provides examples of BDS dataset, ADNCA (Data for Non-Compartmental Analysis), with the addition of new standard variables specific to NCA such as, flags to identify records not included in the analysis, additional dosing variables, etc. It should be noted that this does not imply that naming conventions are required for the name of the ADaM dataset.<\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p>The new <span style=\"text-decoration: underline;\">ADaM Structure for Occurrence Data (OCCDS)<\/span>\u00a0version 1.1 contains three additional examples:<\/p>\n<ul>\n<li><em>Analysis of Adverse Events that Change over Time<\/em> for example, when the sponsor has decided to track changes of severity, causality, or seriousness in an FAAE (Findings About Adverse Events) SDTM domain<\/li>\n<li><em>Analysis of Adverse Events from Multiple Input Domains<\/em> for example, when in a study the individual occurrences of an event of interest are tracked in CE (Clinical Events) but then analyzed together with other adverse events stored in AE (Adverse Events) SDTM domain<\/li>\n<li><em>Analysis of Protocol Deviations<\/em> putting the emphasis on the need to have strong metadata traceability when data-point traceability is not feasible especially, when an ADaM dataset is derived from multiple sources e.g., SDTM and ADaM datasets<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>In addition to the three examples above, the new version of the OCCDS introduces some new &#8220;indexed&#8221; variables e.g., TREMxxFL, where there are multiple periods analysis needs (Example 4, <em>Analysis of Treatment-emergent Adverse Events in a Cross-Over Interaction Study<\/em>, has been modified to show the use of these new variables). Moreover, in the &#8220;Introduction&#8221; section of the document it is clarified that in some instances the number of records in an OCCDS dataset might not match the number of records in the source SDTM dataset, when for example -OCCUR=&#8217;N&#8217; in the source SDTM dataset; the following does not apply to the new define 2.1 SubClass &#8220;ADVERSE EVENT&#8221;.<\/p>\n<p>Finally, the new IG (1.3) documents do not contain any major updates nor any new standard variables, with mainly changes to or addition of text to clarify topics or guidance already available in previous versions of the IG. All the above new IGs are also listed in the ADaM IG.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"font-weight: bold;\"><span style=\"color: #2e308d;\">What&#8217;s new in SDTM<\/span><\/p>\n<p>Covering all the changes in the new standard (2.0) and the new IG (3.4) in one blog post is difficult and it also requires a more in-depth review of the released documents, although CDISC provides a &#8220;Diff&#8221; file with details of changes made to each individual domain.<\/p>\n<p>However, from all the updates I would like to mention the availability of new domains:<\/p>\n<ul>\n<li>From the SDTM PGx IG, the BE (Biospecimen Events), BS (Biospecimen Findings), GF (Genomics Findings) and RELSPEC (Related Specimens) domains (GF was previously named PF in the SDTM PGx IG). Of note, most of the content of the SDTM PGx has been incorporated in the IG 3.4 and therefore the SDTM PGx is now deprecated<\/li>\n<li>CP (Cell Phenotype Findings)<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>As anticipated in the SDTM IG 3.3, the dataset MO (Morphology) has been deprecated and replaced by separated specific morphology findings domains organized by body systems e.g., CV for Cardiovascular System physiological and morphological findings.<\/p>\n<p>Moreover, the SV (Subject Visits) domain now incorporates variables that were proposed with the VE (Visit Events) domain in the draft &#8220;Guidance for Ongoing Studies Disrupted by COVID-19 Pandemic&#8221;<sup>[5]<\/sup> , which also includes new standard SDTM variables such as, SVEPCHGI (Epi\/Pandemic Related Change Indicator) and is available now in the SDTM standard model version 2.0; the domain now also allows the recording of non-occurred planned visits. The SV domain was previously a special-purpose domain and now, according to the SDTM standard version 2.0, it has been moved to an Events class domain; however, the SDTM IG 3.4 still lists the domain under the special-purpose domains and the same in the supplied metadata.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"font-weight: bold;\"><span style=\"color: #2e308d;\">CDISC and Cytel in 2022<\/span><\/p>\n<p>At Cytel, my colleague Silvia Faini and I will continue to help CDISC in 2022 with organizing the CDISC European Interchange (currently the event is planned to be live in Copenhagen 27-28 April and you are all invited to <a href=\"https:\/\/www.cdisc.org\/events\/interchange\/2022-europe-interchange\" target=\"_blank\" rel=\"noopener\">submit your abstract-proposal<\/a> by the end of this week) and organizing the IX CDISC Italian Speaking User Network Meeting, after the successful VIII edition held on December 3, 2021 (full copy of slides available in the CDISC Wiki <sup>[6]<\/sup>).<\/p>\n<p>&nbsp;<\/p>\n<p style=\"font-weight: bold;\"><span style=\"color: #2e308d;\">References:<\/span><\/p>\n<p>[1] <a href=\"https:\/\/www.cdisc.org\/standards\/foundational\/sdtmig\" target=\"_blank\" rel=\"noopener\">SDTM Implementation Guidance Version 3.4<\/a><\/p>\n<p>[2] <a href=\"https:\/\/www.cdisc.org\/standards\/foundational\/sdtm\" target=\"_blank\" rel=\"noopener\">SDTM Version 2.0 <\/a><\/p>\n<p>[3] <a href=\"https:\/\/www.cdisc.org\/standards\/foundational\/adam\" target=\"_blank\" rel=\"noopener\">ADaM Version 2.1 and ADaM Implementation Guidance Version 1.3<\/a><\/p>\n<p>[4] <a href=\"https:\/\/www.lexjansen.com\/pharmasug\/2021\/MD\/PharmaSUG-2021-MD-035.pdf\" target=\"_blank\" rel=\"noopener\">ADaM Implementation Guide for Medical Devices, J. Yang, K. LaPann, S. Faini; PharmaSUG 2021<\/a><\/p>\n<p>[5] <a href=\"https:\/\/www.cdisc.org\/system\/files\/members\/standard\/ta\/Guidance_for_Ongoing_Studies_Disrupted_by_COVID-19.pdf\" target=\"_blank\" rel=\"noopener\">CDISC Guidance for Ongoing Studies Disrupted by COVID-19 Pandemic<\/a><\/p>\n<p>[6] <a href=\"https:\/\/wiki.cdisc.org\/pages\/viewpage.action?pageId=136085596\" target=\"_blank\" rel=\"noopener\">CDISC Italian User Network Page<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"featured_media":3105,"parent":0,"template":"","meta":{"_acf_changed":false},"tags":[76],"by-topic":[414],"by-year":[71],"class_list":["post-3150","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry","tag-blog","by-topic-cdisc","by-year-71"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CDISC SDTM and ADaM: An Explosive 2021 Ending! - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us<\/title>\n<meta name=\"description\" content=\"CDISC recently announced an important update for SDTM and ADaM CDISC models. In this blog, Cytel Data Management expert, Angelo Tinazzi shares a summary of the updates made to the standards and the new Implementation Guidance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CDISC SDTM and ADaM: An Explosive 2021 Ending! - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"og:description\" content=\"CDISC recently announced an important update for SDTM and ADaM CDISC models. In this blog, Cytel Data Management expert, Angelo Tinazzi shares a summary of the updates made to the standards and the new Implementation Guidance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-21T15:16:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/06\/Cytel_Abstract_1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/cdisc-sdtm-and-adam-an-explosive-2021-ending\\\/\",\"url\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/cdisc-sdtm-and-adam-an-explosive-2021-ending\\\/\",\"name\":\"CDISC SDTM and ADaM: An Explosive 2021 Ending! - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/cdisc-sdtm-and-adam-an-explosive-2021-ending\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/cdisc-sdtm-and-adam-an-explosive-2021-ending\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Cytel_Abstract_1.jpg\",\"datePublished\":\"2024-06-10T15:22:29+00:00\",\"dateModified\":\"2024-08-21T15:16:16+00:00\",\"description\":\"CDISC recently announced an important update for SDTM and ADaM CDISC models. In this blog, Cytel Data Management expert, Angelo Tinazzi shares a summary of the updates made to the standards and the new Implementation Guidance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/cdisc-sdtm-and-adam-an-explosive-2021-ending\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/cdisc-sdtm-and-adam-an-explosive-2021-ending\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/cdisc-sdtm-and-adam-an-explosive-2021-ending\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Cytel_Abstract_1.jpg\",\"contentUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Cytel_Abstract_1.jpg\",\"width\":1920,\"height\":1280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/cdisc-sdtm-and-adam-an-explosive-2021-ending\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CDISC SDTM and ADaM: An Explosive 2021 Ending!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\",\"name\":\"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\",\"description\":\"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CDISC SDTM and ADaM: An Explosive 2021 Ending! - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","description":"CDISC recently announced an important update for SDTM and ADaM CDISC models. In this blog, Cytel Data Management expert, Angelo Tinazzi shares a summary of the updates made to the standards and the new Implementation Guidance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/","og_locale":"fr_FR","og_type":"article","og_title":"CDISC SDTM and ADaM: An Explosive 2021 Ending! - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","og_description":"CDISC recently announced an important update for SDTM and ADaM CDISC models. In this blog, Cytel Data Management expert, Angelo Tinazzi shares a summary of the updates made to the standards and the new Implementation Guidance.","og_url":"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/","og_site_name":"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","article_modified_time":"2024-08-21T15:16:16+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/06\/Cytel_Abstract_1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/","url":"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/","name":"CDISC SDTM and ADaM: An Explosive 2021 Ending! - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","isPartOf":{"@id":"https:\/\/cytel.agencyukdev.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/#primaryimage"},"image":{"@id":"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/#primaryimage"},"thumbnailUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Cytel_Abstract_1.jpg","datePublished":"2024-06-10T15:22:29+00:00","dateModified":"2024-08-21T15:16:16+00:00","description":"CDISC recently announced an important update for SDTM and ADaM CDISC models. In this blog, Cytel Data Management expert, Angelo Tinazzi shares a summary of the updates made to the standards and the new Implementation Guidance.","breadcrumb":{"@id":"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/#primaryimage","url":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Cytel_Abstract_1.jpg","contentUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Cytel_Abstract_1.jpg","width":1920,"height":1280},{"@type":"BreadcrumbList","@id":"https:\/\/www.cytel.com\/perspectives\/cdisc-sdtm-and-adam-an-explosive-2021-ending\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cytel.agencyukdev.com\/"},{"@type":"ListItem","position":2,"name":"CDISC SDTM and ADaM: An Explosive 2021 Ending!"}]},{"@type":"WebSite","@id":"https:\/\/cytel.agencyukdev.com\/#website","url":"https:\/\/cytel.agencyukdev.com\/","name":"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","description":"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cytel.agencyukdev.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives\/3150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media\/3105"}],"wp:attachment":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media?parent=3150"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/tags?post=3150"},{"taxonomy":"by-topic","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-topic?post=3150"},{"taxonomy":"by-year","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-year?post=3150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}